It is hypothesized that anti-IL-4 and anti-IL-13 therapies could decrease asthma exacerbations by inhibiting eosinophilic and airway inflammation. Reducing asthmaexacerbation risk is a key target of disease management. The improvements in asthma-related quality of life with dupilumab treatment may contribute to preventing severe asthmaexacerbations, particularly in patients with nasal polyposis.
Real-life experience of severe asthma patients on Dupilumab treatment in Pordenone’s Hospital
Miriana d’Alessandro;
2022-01-01
Abstract
It is hypothesized that anti-IL-4 and anti-IL-13 therapies could decrease asthma exacerbations by inhibiting eosinophilic and airway inflammation. Reducing asthmaexacerbation risk is a key target of disease management. The improvements in asthma-related quality of life with dupilumab treatment may contribute to preventing severe asthmaexacerbations, particularly in patients with nasal polyposis.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
